Anavar vs Winstrol: Why Winstrol Is Worse for Women

Oxandrolone (Anavar) and stanozolol (Winstrol) frequently appear together in beginner female AAS discussions because both are oral, both are DHT derivatives, and both have decades of community use in female bodybuilders and physique athletes. The grouping is misleading. The compounds have very different practical profiles, and winstrol is the worse choice on essentially every safety dimension that women can actually monitor.

Anavar (oxandrolone) is a 2-oxa-17-alpha-methyl DHT derivative with about 28 percent renal clearance, which moderates its hepatic load relative to other 17-AA orals. Female doses are typically 5 to 20 mg/day. The signature pharmacological feature is aggressive SHBG suppression and the disproportionate free testosterone spike that follows.

Winstrol (stanozolol) is a 17-alpha-methyl DHT derivative with a pyrazole ring attached. The structural modifications produce three downstream problems: severe lipid impact (HDL crash often exceeding 50 percent at modest doses), notable joint pain (mechanism debated; likely involves both prostaglandin pathways and dry-joint subjective experience from suppressed estradiol activity), and a more potent androgenic per-mg profile. Cycle length is typically limited by joint tolerance more than by lipid or liver markers.

The literature comparing the two head-to-head in women is essentially nonexistent. The class-effect lipid data from Hartgens and others consistently shows winstrol producing the worst HDL crashes of any AAS, while anavar is in the middle of the pack.

Lipid impact (the biggest gap):

• Anavar: 20 to 45 percent HDL crash at 10 to 20 mg/day. ApoB rises 30 to 40 percent. Triglycerides paradoxically drop. Recovery 4 to 12 weeks.
• Winstrol: 50 to 80 percent HDL crash at modest doses (5 to 10 mg/day oral). ApoB rises sharply. ApoA-1 (the cardioprotective apolipoprotein) drops more on winstrol than on any other commonly used AAS. Recovery 8 to 16 weeks. The Glazer 1991 review and Hartgens data consistently rank stanozolol at or near the top for atherogenic lipid impact.

Joint pain:

• Anavar: neutral to slight joint dryness, typically only if HPG axis is fully shut down and estradiol crashes. Most female users don't report joint issues.
• Winstrol: notorious for joint pain. The mechanism is debated, but the practical effect is real: many users have to stop cycles early because of knee, shoulder, or elbow discomfort. Training quality suffers measurably. This is the single most common reason women abandon a winstrol cycle.

Hepatic load:

• Anavar: mild but real, ALT typically 1.5 to 3x ULN, recovery 2 to 4 weeks. About 28 percent renal clearance moderates exposure.
• Winstrol: heavier hepatic load than anavar. ALT often 2 to 4x ULN at 10 mg/day oral. The injectable form (suspension) carries lower hepatic risk but is rarely used by women because of injection pain and frequency requirements.

Virilization risk per mg:

• Anavar: moderate. Amplified by the signature SHBG crash which spikes free testosterone disproportionately.
• Winstrol: higher per mg. The androgenic-to-anabolic ratio is more androgenic than anavar. Voice changes, clitoral hypertrophy, and body hair growth appear at lower cumulative exposures with winstrol than with anavar at comparable physique impact.

Detection time (for tested athletes):

• Anavar: about 3 weeks
• Winstrol: 2 months (one of the longest detection windows in the AAS catalog)

SHBG suppression:

• Anavar: 70 to 90 percent at typical female doses (the signature effect)
• Winstrol: 60 to 80 percent at 10 mg/day oral; similar disproportionate free T effect but typically at higher absolute androgen loads

Sourcing and cost:

• Anavar: widely available, moderate to high cost, more often authentic.
• Winstrol: widely available, cheap, generally authentic supply. Sourcing risk is lower than primo but still present (oral winstrol is sometimes contaminated with anavar or vice versa).

Side effects beyond lipids and joints:

• Anavar: HDL crash, mild ALT elevation, SHBG crash, virilization risk
• Winstrol: severe HDL crash, joint pain, ALT elevation, virilization risk, occasionally tendinopathy (small case series), dry skin and hair

Choose anavar over winstrol:

• Almost always, when anavar is available
• When training quality matters (no joint pain risk to derail your program)
• When cardiovascular risk profile matters (lipid impact is meaningfully lower)
• When cycle length needs to exceed 6 weeks (winstrol joint pain often forces early stop)
• When you can tolerate the hepatic load and have a TUDCA protocol in place

Choose winstrol over anavar:

• Only in narrow cases. A competitor's cutting peak where the dry, hard look matters more than longer-term lipid profile, and where the cycle is short enough (3 to 4 weeks) to avoid the worst joint pain. Even here, masteron or anavar are arguably better choices.
• If anavar is unavailable in your region and you have a reliable winstrol source. Even then, the bar is high.

Choose neither:

• If you haven't run baseline bloodwork
• If you're already low on HDL (under 50 mg/dL premenopausal female baseline)
• If you have any joint history or current training niggles (winstrol will worsen them)
• If you're hoping for a "safe" women's AAS. There isn't one; anavar is less unsafe than winstrol.

Starting doses in women:

• Anavar: 5 to 10 mg/day, single dose with food. Titrate to 15 to 20 mg after week 4 bloodwork if tolerated.
• Winstrol: 5 mg/day oral, split into two doses (winstrol has a short half-life). Most experienced female users do not exceed 10 mg/day total. Cycle length 4 to 6 weeks maximum.